Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 5, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
During a Focused Topic Session at the 2022 Alzheimer’s Association International Conference, NeurologyLive® inquired with a panel of experts about the possibility of exploring a combination approach to Alzheimer disease as the future of treatment.
Catch up on any of the neurology news headlines pertaining to FDA actions that you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.
In the latest edition of our Q&A series, the professor of psychiatry and cell biology at NYU Langone provided insight on new findings that uncover the sources of neuronal damage in Alzheimer disease that may explain the failures of antiamyloid therapies.
The medical director of the Deanna and Sidney Wolk Center for Memory Health provided background on his new study using multimodal digital biomarkers to classify patients with mild cognitive impairment in a conversation with NeurologyLive® from AAIC 2022.
The nephrologist at Mayo Clinic provided insight on new data showing elevated extracellular vesicles of neurovascular origin in women with a history of severe preeclampsia years after pregnancy in a conversation with NeurologyLive® from AAIC 2022.